Viemed heads into its third-quarter report with a split personality. The clinical engine looks healthier than it has in a year, with ventilator census back in growth after the coverage reset under the new national coverage framework, yet the profit line has moved the other way. The stock has sided with the skeptics. Shares are down 18% since the last report, trailing the S&P 500 by roughly 21 percentage points, which suggests the market cared more about the trimmed EBITDA outlook than the record revenue.
The Street is looking for earnings of $0.12 per share on revenue of $80.8 million. That would mean EPS growth of about 33% from the year-ago $0.09 and a sizable jump from last quarter's $0.07, while revenue would rise about 12%. The top-line figure is a noticeable deceleration from the 24% growth posted in the second quarter, so the revenue bar is not especially demanding. Management's full-year range of $314 million to $320 million, with the low end raised for the second straight quarter, implies roughly $80 million to $83 million per quarter in the back half after first-half sales of about $153.5 million. Consensus sits in the lower half of that implied band, leaving room for an upside surprise if the summer momentum held.
Profitability is where the math gets tighter. Adjusted EBITDA margin slid to 17.6% last quarter from 19% in the first quarter and about 22.4% a year earlier, and management cut its full-year EBITDA guide to $64 million to $68 million while softening the margin target to at least 20%. First-half EBITDA works out to roughly $28 million, which means the second half needs something like $36 million to $40 million, or margins in the low-to-mid 20s. That is a meaningful step up from where the company has been running. Management attributed the squeeze to temporary items: duplicate costs from bringing sleep resupply operations and the call center in-house, transition expenses tied to a new national maternal health distributor, capacity investments, and a phantom stock revaluation driven by share-price gains. The last of these may work in Viemed's favor this time, since the stock has fallen, but the other costs need to start rolling off for the guide to look credible. A third straight quarter of margin compression would challenge the idea that the pressure is transitory rather than structural.
The structural piece is real. Rental revenue has dropped to about 68% of the mix from roughly 76% a year ago as equipment sales, PAP, resupply and maternal health grow faster. That shift lowers EBITDA margin even as it reduces capital intensity, which is why the net capex outlook was trimmed to 8.5% to 10% of revenue. Investors should judge the quarter through free cash flow as well as EBITDA; trailing free cash flow of $34.4 million is the best counterargument to margin worries.
On the operating side, validation looks like another quarter of net ventilator patient additions on top of the record 12,635 active patients, continued gains in compliance, and evidence that Medicare Advantage approvals are sustaining setup volume. Sleep and resupply, which posted a record PAP quarter and 47% annual resupply growth, should benefit from the intake automation that cut qualification times to under an hour. The fourth sales division and expanded geographic coverage are newer bets whose payoff should start appearing in setups.
Sentiment remains bearish but less so than a quarter ago, and the stock at $9.68 sits just above its 200-day average and in the lower portion of its post-earnings range. The central question is simple: can Viemed show that its investment-heavy growth is beginning to convert into operating leverage? Census growth plus visible margin recovery would keep the improving narrative intact; strong revenue with flat margins would likely leave the market unconvinced.